[{"address1": "822 A1A North", "address2": "Suite 306", "city": "Ponte Vedra", "state": "FL", "zip": "32082", "country": "United States", "phone": "904 300 0701", "website": "https://www.cadrenal.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.", "fullTimeEmployees": 3, "companyOfficers": [{"maxAge": 1, "name": "Mr. Quang X. Pham", "age": 58, "title": "Chairman & CEO", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 822173, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew K. Szot CPA, CPA", "age": 49, "title": "Co-Founder & CFO", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": 359605, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Douglas W. Losordo FACC, FAHA, M.D.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": 23360, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.82, "open": 2.09, "dayLow": 1.0206, "dayHigh": 2.17, "regularMarketPreviousClose": 1.82, "regularMarketOpen": 2.09, "regularMarketDayLow": 1.0206, "regularMarketDayHigh": 2.17, "forwardPE": -3.1333334, "volume": 2302471, "regularMarketVolume": 2302471, "averageVolume": 214248, "averageVolume10days": 803840, "averageDailyVolume10Day": 803840, "bidSize": 1000, "askSize": 800, "marketCap": 18362148, "fiftyTwoWeekLow": 0.395, "fiftyTwoWeekHigh": 3.14, "fiftyDayAverage": 0.71694, "twoHundredDayAverage": 0.95913, "currency": "USD", "enterpriseValue": 9279861, "floatShares": 3917244, "sharesOutstanding": 13022800, "sharesShort": 40207, "sharesShortPriorMonth": 50906, "sharesShortPreviousMonthDate": 1702598400, "dateShortInterest": 1705017600, "sharesPercentSharesOut": 0.0031, "heldPercentInsiders": 0.58472997, "heldPercentInstitutions": 0.08494, "shortRatio": 0.28, "shortPercentOfFloat": 0.0073, "impliedSharesOutstanding": 13022800, "bookValue": 0.672, "priceToBook": 2.0982141, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -12832846, "forwardEps": -0.45, "enterpriseToEbitda": -1.207, "52WeekChange": -0.24166667, "SandP52WeekChange": 0.17144287, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CVKD", "underlyingSymbol": "CVKD", "shortName": "Cadrenal Therapeutics, Inc.", "longName": "Cadrenal Therapeutics, Inc.", "firstTradeDateEpochUtc": 1674225000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ba078ec3-1bff-3797-99d9-a2e1a25e88f8", "messageBoardId": "finmb_1793167154", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.41, "targetHighPrice": 4.0, "targetLowPrice": 3.0, "targetMeanPrice": 3.5, "targetMedianPrice": 3.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 9109445, "totalCashPerShare": 0.7, "ebitda": -7688326, "totalDebt": 27223, "quickRatio": 16.164, "currentRatio": 16.463, "debtToEquity": 0.311, "operatingCashflow": -3235618, "financialCurrency": "USD", "trailingPegRatio": null}]